|
|
|
| The London Biotechnology Show, taking place at ExCeL London on 18-19 June, is a premier event driving advancements in biotechnology for the medical and healthcare sectors. Serving as a global platform, it unites industry leaders to foster innovation, collaboration, and progress. With a focus on transformative breakthroughs, the event aims to accelerate the impact of biotechnology in the UK and worldwide. Register now. |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | Those of us who attended the Alliance for mRNA Medicines’ inaugural Ascent conference last fall had the opportunity to hear from Zdravka Medarova of TransCode Therapeutics on her experiences working in the oligo sector. Here, I summarize some of her learnings and/or suggestions for the encoding RNA field as we set out to develop mRNA therapeutics for oncology. | |
|
|
|
By Tiffany Lucas, Ph.D., and Ifty Saiyed, Eliquent Life Sciences | The U.K.'s MHRA has released a new draft guideline outlining best practices for drug product design, CMC, and manufacturing of mRNA cancer immunotherapies using LNP delivery systems. The public comment period ends March 31. | |
|
|
|
| Solutions For CQA Analysis Of IVT mRNA-Based Biotherapeutics | Application Note | Agilent Technologies | Discover new innovative solutions for mRNA analysis, enhancing accuracy and efficiency in IVT mRNA workflows including advanced technologies and methodologies to optimize your research and development processes. |
|
|
| De-Risk mRNA Regulatory Approvals | Infographic | MilliporeSigma | Gain insight into how you can de-risk mRNA regulatory approvals with critical quality attribute characterization and lot release testing. |
|
|
|
|
| Hepatitis B - Global Clinical Trial Landscape | White Paper | Novotech | As Hepatitis B virus (HBV) clinical trials advance, refining therapeutic endpoints and integrating novel treatment strategies are essential to transforming Hepatitis B management. |
|
|
| Navigating The mRNA Regulatory Landscape Post-COVID | Article | Roche CustomBiotech | While organizations adapt to evolving safety and efficacy standards for mRNA, collaboration remains essential for navigating challenges like differing regional requirements, higher dosing needs, and analytical complexities. |
|
|
.png){kind=logo}
